CEPHODOXIAA 100 DT: Cefpodoxime Proxetil Dispersible Tablets for Kids & Adults

 CEPHODOXIAA 100 DT, manufactured by Steris Healthcare, contains Cefpodoxime Proxetil 100 mg in a dispersible tablet (DT) format, formulated as a third-generation oral cephalosporin antibiotic. The dispersible form allows the tablet to be dissolved in water, making it easier to swallow — a particularly useful feature for children, elderly patients, and individuals with difficulty swallowing solid tablets. It is prescribed for mild to moderate bacterial infections including throat infections (tonsillitis and pharyngitis), acute otitis media, uncomplicated skin and soft tissue infections, and uncomplicated urinary tract infections. Its lower strength makes it well suited for pediatric dosing and for adult patients requiring a lower or titrated dose compared to standard 200 mg formulations.

Why It's Important

Bacterial throat, ear, skin, and urinary infections are common across all age groups, and children in particular often struggle with swallowing conventional tablets, leading to poor treatment compliance if an appropriate dosage form isn't available. CEPHODOXIAA 100 DT's dispersible format addresses this practical barrier while still delivering the reliable, broad-spectrum bactericidal action expected of third-generation cephalosporins. Timely and properly dosed therapy prevents complications such as recurrent ear infections, spread of streptococcal throat infections, or progression of untreated UTIs, while the easier administration format supports better adherence to the full antibiotic course — a key factor in preventing antibiotic resistance.

Key Benefits 

What are the benefits?

• Effective against common throat, ear, skin, and urinary tract infections
• Dispersible tablet format eases administration in children and elderly patients
• Broad-spectrum activity covering key gram-positive and gram-negative pathogens
• Lower strength suitable for pediatric and dose-titrated adult use
• Twice-daily dosing supports consistent treatment compliance
• Manufactured under WHO-GMP and ISO 9001:2018 certified facility standards by Steris Healthcare, ensuring consistent quality and potency

Side Effects

Common side effects are usually mild and may include diarrhea, nausea, mild abdominal discomfort, or loose stools. These typically resolve as treatment progresses or shortly after completing the course.

Serious Side Effects 

Patients should seek immediate medical attention for signs of a severe allergic reaction — facial or throat swelling, difficulty breathing, or widespread hives — as well as persistent or bloody diarrhea (which may indicate Clostridioides difficile-associated colitis), or yellowing of the skin or eyes suggesting liver involvement. These symptoms warrant urgent discontinuation and medical review.

Available Substitute 

Several branded Cefpodoxime Proxetil dispersible tablet formulations are available in the Indian pharmaceutical market at comparable strengths. Patients should not switch brands without physician guidance, as differences in dispersibility, excipients, and manufacturing quality can influence dosing accuracy and clinical outcomes, particularly in pediatric use.

Dosage Guidelines 

Dosage is determined by the treating physician based on patient age, body weight, and the type and severity of infection. The tablet should be dispersed in a small amount of water before administration and taken with food to improve absorption and reduce gastrointestinal discomfort. It is typically given twice daily, and the full prescribed course must be completed even after symptoms improve, to ensure complete bacterial clearance. Missed doses should be taken as soon as remembered, without doubling the next dose.

Precautions & Warnings

CEPHODOXIAA 100 DT should not be used in patients with known hypersensitivity to cephalosporin antibiotics, and caution is advised in those with a history of penicillin allergy due to possible cross-reactivity. Dose adjustment may be necessary in patients with renal impairment. It should be used carefully in individuals with a history of gastrointestinal disorders, particularly colitis. Concurrent use of antacids or H2-receptor blockers may reduce drug absorption and should be spaced apart from dosing as advised by the physician.

Mechanism of Action

CEPHODOXIAA 100 DT works by inhibiting bacterial cell wall synthesis. As a prodrug, Cefpodoxime Proxetil is converted after absorption into its active form, cefpodoxime, which binds to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. This binding interferes with the cross-linking of peptidoglycan strands essential to cell wall integrity, causing the bacterial cell wall to weaken and rupture under osmotic pressure, resulting in bacterial death. Its third-generation cephalosporin structure provides enhanced resistance to certain bacterial beta-lactamase enzymes, extending its effectiveness against a broader range of gram-negative organisms compared to earlier cephalosporin generations.

Conclusion

CEPHODOXIAA 100 DT by Steris Healthcare combines the proven broad-spectrum efficacy of third-generation cephalosporin therapy with a practical, easy-to-administer dispersible format ideal for children and patients with swallowing difficulties. This makes it a convenient and reliable choice for managing common bacterial infections while supporting better treatment adherence. As with all antibiotics, use should be guided by a registered physician, with the complete course finished to ensure effective bacterial clearance and reduce resistance risk.